Glucose control in home-isolated adults with type 1 diabetes affected by COVID-19 using continuous glucose monitoring

被引:8
|
作者
Longo, M. [1 ,2 ]
Scappaticcio, L. [1 ]
Petrizzo, M. [3 ]
Castaldo, F. [2 ]
Sarnataro, A. [1 ]
Forestiere, D. [1 ,2 ]
Caiazzo, F. [1 ,2 ]
Bellastella, G. [1 ,2 ]
Maiorino, M., I [1 ,2 ]
Capuano, A. [4 ]
Esposito, K. [1 ,3 ]
机构
[1] Univ Campania Luigi Vanvitelli, Dept Adv Med & Surg Sci, Piazza Luigi Miraglia 2, I-80138 Naples, Italy
[2] Univ Campania Luigi Vanvitelli, Div Endocrinol & Metab Dis, Piazza Luigi Miraglia 2, I-80138 Naples, Italy
[3] Univ Campania Luigi Vanvitelli, Unit Diabet, Naples, Italy
[4] Univ Campania Luigi Vanvitelli, Campania Reg Ctr Pharmacovigilance & Pharmacoepid, Dept Expt Med, Sect Pharmacol L Donatelli, Naples, Italy
关键词
Type; 1; diabetes; COVID-19; Glucose control; CGM; MDI; CSII; MORTALITY; ASSOCIATION; OUTCOMES;
D O I
10.1007/s40618-021-01669-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose This study is aimed at evaluating changes in metrics of glucose control in home-isolated patients with type 1 diabetes and COVID-19 using a continuous glucose monitoring (CGM) system. Methods We included adults aged 18-45 years with type 1 diabetes, using CGM, followed by telemedicine at a Southern Italian University Hospital. Thirty-two home-quarantined subjects with SARS-CoV-2 positive swab constituted the COVID-19 group. Thirty age-matched diabetic individuals without COVID-19 formed the control group. The effects of COVID-19 on glycemic control in patients infected were assessed at different time points [2 weeks before-COVID-19 (Time 1), 2 weeks during-COVID-19 (Time 2) and 2 weeks after COVID-19 (Time 3)] and compared with those without infection. Results A significant reduction of TIR (Time 1 vs Time 2, %, 60.1 +/- 16.6 vs 55.4 +/- 19.2, P = 0.03), associated with a significant increase of TAR level 2 (10.1 +/- 7.3 vs 16.7 +/- 12.9, P < 0.001), GMI (7.1 +/- 0.6 vs 7.5 +/- 0.8, P < 0.001), CV (37.3 +/- 7.1 vs 39.6 +/- 7.0, P = 0.04), mean glucose values (mg/dL, 160.2 +/- 26.5 vs 175.5 +/- 32.6, P = 0.001) and standard deviation (59.2 +/- 13.1 vs 68.6 +/- 17.7, P = 0.001) was observed in patients with COVID-19. No significant change of glycemic metrics was found in the NO COVID-19 group across the time. Conclusion Young home-isolated patients with type 1 diabetes and COVID-19 showed a worsening of glucose control during COVID-19, as compared with age-matched diabetic subjects without the infection.
引用
下载
收藏
页码:445 / 452
页数:8
相关论文
共 50 条
  • [41] Continuous home monitoring of glucose - Improved glycemic control with real-life use of continuous glucose sensors in adult subjects with type 1 diabetes
    Garg, Satish K.
    Kelly, William C.
    Voelmle, Mary K.
    Ritchie, Peter J.
    Gottlieb, Peter A.
    McFann, Kim K.
    Ellis, Samuel L.
    DIABETES CARE, 2007, 30 (12) : 3023 - 3025
  • [42] Glycemic control using intermittently scanned continuous glucose monitoring in patients with diabetes requiring methylprednisolone therapy for severe COVID-19
    Uchihara, Masaki
    Kodani, Noriko
    Bouchi, Ryotaro
    Saito, Sho
    Miyazato, Yusuke
    Sugimoto, Hirofumi
    Umamoto, Kotaro
    Kobayashi, Michi
    Ihana-Sugiyama, Noriko
    Ohsugi, Mitsuru
    Tanabe, Akiyo
    Ueki, Kohjiro
    Takasaki, Jin
    Hojo, Masayuki
    Kajio, Hiroshi
    GLOBAL HEALTH & MEDICINE, 2022, 4 (06): : 336 - 340
  • [43] Glycemic Control and Socioeconomic Status in Children with Type 1 Diabetes Using Continuous Glucose Monitoring
    Ladd, Jennifer
    Rahme, Elham
    Zuijdwijk, Caroline
    Goldbloom, Ellen
    Shulman, Rayzel
    Pacaud, Daniele
    von Oettingen, Julia
    Nakhla, Meranda
    HORMONE RESEARCH IN PAEDIATRICS, 2022, 95 (SUPPL 1): : 62 - 63
  • [44] Improvement of Metabolic Control in Children with Type 1 Diabetes Using Continuous Glucose Monitoring Devices
    Gil-Poch, Estela
    Roco-Rosa, Maria
    Javier Arroyo-Diez, Francisco
    HORMONE RESEARCH IN PAEDIATRICS, 2019, 91 : 637 - 638
  • [45] Effect of Continuous Glucose Monitoring on Glycemic Control in Children with Type 1 Diabetes
    Tantivit, Nessa
    Kaulfers, Anne-Marie
    HORMONE RESEARCH IN PAEDIATRICS, 2022, 95 (SUPPL 1): : 48 - 49
  • [46] Continuous glucose monitoring in the hospital: an update in the era of COVID-19
    Gothong, Chikara
    Singh, Lakshmi G.
    Satyarengga, Medha
    Spanakis, Elias K.
    CURRENT OPINION IN ENDOCRINOLOGY DIABETES AND OBESITY, 2022, 29 (01) : 1 - 9
  • [47] Sustained Benefit of Continuous Glucose Monitoring on A1C, Glucose Profiles, and Hypoglycemia in Adults With Type 1 Diabetes
    Beck, Roy W.
    Xing, Dongyuan
    Gilliam, Lisa
    Hirsch, Irl
    Kollman, Craig
    Laffel, Lori
    Ruedy, Katrina J.
    Tamborlane, William V.
    Weinzimer, Stuart
    Wolpert, Howard
    DIABETES CARE, 2009, 32 (11) : 2047 - 2049
  • [48] Blood Glucose Control Strategy for Type 2 Diabetes Patients With COVID-19
    Futatsugi, Hiroyuki
    Iwabu, Masato
    Okada-Iwabu, Miki
    Okamoto, Koh
    Amano, Yosuke
    Morizaki, Yutaka
    Kadowaki, Takashi
    Yamauchi, Toshimasa
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2020, 7
  • [49] Real-world continuous glucose monitoring in adults with type 1 and type 2 diabetes
    Sarri, Grammati
    Zabotka, Luke
    Freitag, Andreas
    Claire, Ravinder
    Wangge, Grace
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 432 - 433
  • [50] Performance Assessment of Three Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes
    Koelle, Julia
    Eichenlaub, Manuel
    Mende, Jochen
    Link, Manuela
    Vetter, Beatrice
    Safary, Elvis
    Pleus, Stefan
    Haug, Cornelia
    Freckmann, Guido
    JOURNAL OF DIABETES SCIENCE AND TECHNOLOGY, 2023,